Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK's Struggle For Reclassification

Nonprofit medical research organization the Usona Institute shared the results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for 104 adults with Major Depressive Disorder (MDD,) providing further evidence of the psychedelic's antidepressant capabilities.

COMPASS Pathways(NASDAQ:CMPS), one of the biggest players in the psychedelics biotech space today, shared the results from research on the potential of its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression (TRD.)

Meanwhile, U.K. drug policy and reform is...